loader image

Piśmiennictwo

  1. Oyesola OO, Tait Wojno ED. Prostaglandin regulation of type 2 inflammation: From basic biology to therapeutic interventions. Eur J Immunol. 2021 Oct;51(10):2399-2416. doi: 10.1002/eji.202048909. Epub 2021 Sep 7. PMID: 34396535; PMCID: PMC8843787.
  2. Franciosi JP, Liacouras CA. Eosinophilic esophagitis. Immunol Allergy Clin North Am 2009; 29(1): 19-27.
  3. Padia R, Curtin K, Peterson K, Orlandi RR, Alt J. Eosinophilic esophagitis strongly linked to chronic rhinosinusitis. Laryngoscope. 2016 Jun;126(6):1279-83. doi: 10.1002/lary.25798. Epub 2015 Nov 26. PMID: 26606888.
  4. Global Initiative for Asthma (GINA). “Global Strategy for Asthma Management and Prevention,” 2022. Available at: https://ginasthma.org/gina-reports/. Accessed July 2022.
  5. Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020; 58:1–464.
  6. Silverberg JI, Hanifin JM. Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. The Journal of Allergy and Clinical Immunology. 2013; 132:1132–8.
  7. T. Zuberbier, S. Orlow and A. Paller, “Patient perspectives on the management of atopic dermatitis,” Journal of Allergy and Clinical Immunology, vol. 118, no. 1, pp. 226-232, 2006.
  8. Price D, Fletcher M, van der Molen T. Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. NPJ Prim Care Respir Med 2014; 24:14009.
  9. P. Marcus, R. Arnold and S. Ekins, “A retrospective randomized study of asthma control in the US: results of the CHARIOT study,” Current Medical Research and Opinion, vol. 24, no. 12, pp. 3443-3452, 2008.
  10. E. Ponte, R. Franco and H. Nascimento, “Lack of control of severe asthma is associated with co-existence of moderate-to-severe rhinitis,” Allergy, vol. 63, no. 5, pp. 564-569, 2008. polyps and asthma: clinical and radiological features, allergy and inflammation markers,” Medicina, vol. 44, no. 4, pp. 257-265, 2008.
  11. C. Rand, R. Wright and M. Cabana, “Mediators of asthma outcomes,” J Allergy Clin Immunol, vol. 129, no. 301, pp. 136-141, 2012.
  12. D. Stull, L. Roberts and L. Frank, “Relationship of nasal congestion with sleep, mood, and productivity,” Current Medical Research and Opinion, vol. 23, no. 4, pp. 811-819, 2007.
  13. S. Nordic, E. Blomgvist and P. Olsson, “Effects of smell loss on daily life and adopted coping strategies in patients with nasal polyposis with asthma,” Acta Oto-Laryngologica, vol. 131, no. 8, pp. 826-832, 2011.
  14. M. Iskedjian, C. Piwko and N. Shear, “Topical calcineurin inhibitors in the treatment of atopic dermatitis: a meta-analysis of current evidence,” Am J Clin Dermatol, vol. 5, no. 4, pp. 267-279, 2004.
  15. J. Cury Martins, C. Martins and V. Aoki, “Topical tacrolimus for atopic dermatitis (Review),” The Cochrane Collaboration. Published by JohnWiley & Sons, Ltd., 2016.
  16. S. Meggitt, J. Gray and N. Reynolds, “Azathioprine dosed by thiopurine methyltransferase activity for moderate to severe atopic eczema: a double-blind, randomised controlled trial,” Lancet, vol. 367, no. 9513, pp. 839-846, 2006.
  17. D. Ashcroft, P. Dimmock and R. Garside, “Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials,” BMJ, vol. 330, no. 7490, pp. 516-522, 2005.
  18. M. Schram, E. Roekevisch and M. Leeflang, “A randomized trial of methotrexate versus azathioprine for severe atopic eczema,” J Allergy Clin Immunol, vol. 128, no. 2, pp. 353- 359, 2011.
  19. Philpott, C. Hopkins and S. Erskine, “The burden of revision sinonasal surgery in the UK – data from the Chronic Rhinosinusitis Epidemiology.
  20. Seys SF, Scheers H, Van den Brande P, et al. Cluster analysis of sputum cytokine-high profiles reveals diversity in T(h)2-high asthma patients. Respir Res. 2017;18(1):39. doi:10.1186/s12931-017-0524-y.
  21. Jackson DJ, Aljamil N, Roxas C, et al. The ‘T2-low’ asthma phenotype: could it just be T2-high asthma treated with corticosteroids? Thorax. 2018;73(suppl 4): A124-A125. Abstract P48.
  22. Khan, Asif et al. “Type 2 inflammation-related comorbidities among patients with asthma, chronic rhinosinusitis with nasal polyps, and atopic dermatitis”. European Respiratory Journal 2020; 56: Suppl. 64, 232.